Phase 2 Evidence and Impact Analysis
Article 1 — Nanoplate dPCR for HPV ctDNA (PMID 42014803)
🔴 Early cancer detection or prevention
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 7 | Nanoplate format addresses a known dPCR sensitivity limitation for low-copy ctDNA; multiplex HPV16/18/31 in one assay with prospective registered-trial validation is meaningfully incremental over standard dPCR |
| Clinical Relevance | 8 | 98/100% sensitivity/specificity with longitudinal remission/relapse prediction directly displaces or augments imaging-based surveillance in cervical cancer follow-up |
| Population Reach | 7 | Cervical cancer is the 4th most common cancer in women globally; high burden in LMICs where HPV-related disease disproportionately strikes underserved populations |
| Implementation Speed | 6 | dPCR infrastructure exists in cancer centers; nanoplate format requires specific instrumentation; regulatory clearance needed; not yet guideline-level |
| Evidence Strength | 7 | Prospective, registered clinical trial in 87 patients; 98% sens/100% spec is strong; single-center, abstract-only, small-N limits full appraisal |
Key quantitative result: 98% sensitivity, 100% specificity (pre-treatment); longitudinal ctDNA clearance correlated with remission (effect size not quantified in abstract).
External validation: None reported; single registered-trial cohort.
Main limitation: Single-center, n=87, abstract-only; no data on positive predictive value in low-prevalence surveillance context; head-to-head vs. imaging not powered.
Equity implications: Cervical cancer disproportionately affects women in LMICs; however, nanoplate dPCR instrumentation may be inaccessible in resource-limited settings — the population most in need may benefit least initially.
Evidence Maturity: Validated ✓ (confirmed)
Article 2 — EV Proteomics for 177Lu-PSMA Outcomes (PMID 42013849)
🟠 Novel or significantly improved treatment
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 8 | First systematic shotgun EV proteomics study (5,137 proteins) for 177Lu-PSMA-617 outcome prediction; identifies B7-H3, Trop-2, STEAP1 as druggable EV surface markers in this specific treatment context |
| Clinical Relevance | 7 | Biomarker stratification for lutetium-PSMA — an approved therapy — is a near-term need; identifies combination targets for resistant mCRPC patients |
| Population Reach | 6 | mCRPC affects ~50,000 US men/year; globally significant but a defined oncology-specialist population; 177Lu-PSMA is approved but access varies |
| Implementation Speed | 4 | Shotgun proteomics is not routine clinical infrastructure; validated biomarker panels must be developed from these discovery findings before clinical use |
| Evidence Strength | 7 | Prospective design, n=100, high-impact journal (Cell Reports Medicine), companion PSMA-PET imaging; abstract-only, observational, requires independent validation |
Key quantitative result: PSMA, B7-H3, Trop-2, STEAP1 EV levels associated with worse OS; PSMA+/EpCAM+ and PSMA-/EpCAM+ CTCs associated with worse PFS and OS (specific HRs/p-values not reported in abstract).
External validation: None reported; discovery cohort requiring prospective validation.
Main limitation: Observational discovery study; shotgun proteomics requires translation to a clinically deployable assay; abstract-only precludes full methodological review.
Equity implications: mCRPC disproportionately affects older, Black men (higher prostate cancer incidence); 177Lu-PSMA access is limited globally; this biomarker platform may further concentrate benefit in well-resourced centers.
Evidence Maturity: Validated → revised to Exploratory-to-Validated (discovery proteomics study; validated in single cohort but not independently replicated)
Article 3 — MM Consensus Recommendations (PMID 42014940)
🟢 Near-term implementable
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 4 | Synthesizes existing evidence rather than generating new data; quadruplet therapy and MRD guidance are not new concepts, but consensus formalization has value |
| Clinical Relevance | 7 | Directly actionable for community oncologists managing MM across disease stages; CAR-T referral timing and MRD-guided maintenance are practical decision points |
| Population Reach | 6 | ~200,000 US MM patients; globally significant hematologic malignancy |
| Implementation Speed | 8 | Consensus recommendations are designed for immediate adoption; no regulatory barriers; changes ordering behavior and referral patterns |
| Evidence Strength | 5 | Modified Delphi, 16 experts, 51 questions — structured but not data-driven; consensus methodology inherently limits evidence grade |
Key quantitative result: 11 consensus recommendations; no primary efficacy data.
External validation: Reflects synthesis of existing trial data; not independently validated as new evidence.
Main limitation: US-centric expert panel; consensus ≠ evidence; may entrench current practice patterns rather than challenge them; abstract-only.
Equity implications: Quadruplet induction and CAR-T require specialized centers; community oncologists in underserved areas may receive the guidance but lack the infrastructure to implement it — potential to widen care disparities.
Evidence Maturity: Potentially Practice-Changing ✓ (confirmed, within the limits of consensus methodology)
Article 4 — APSevLM Acute Pancreatitis LLM (PMID 42013267)
⚪ Promising but preliminary
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 6 | LLM integrating clinical + imaging + expert knowledge for severity prediction is novel in framing; AI triage for pancreatitis is an active but not crowded field |
| Clinical Relevance | 6 | Early severity triage drives ICU admission decisions; outperforming BISAP/MCTSI is clinically meaningful but AUC 0.857 is solid rather than transformative |
| Population Reach | 6 | Acute pancreatitis is common (~275,000 US hospitalizations/year); severity prediction applicable broadly |
| Implementation Speed | 4 | LLM deployment requires EHR integration and prospective validation; retrospective design requires prospective confirmation |
| Evidence Strength | 5 | Retrospective, 500+ patients, medium confidence classification; no external validation cohort reported; abstract-only |
Key quantitative result: AUC 0.857 vs. BISAP, MCTSI, and standard ML models (no specific comparator AUC values in abstract).
External validation: Not reported.
Main limitation: Retrospective single-center design; LLM "expert knowledge" integration is opaque without full methods review; medium classification confidence.
Equity implications: AI triage tools trained in single-center cohorts may underperform in resource-limited settings or across ethnic groups with different disease profiles.
Evidence Maturity: Validated → revised to Exploratory (retrospective, no external validation)
Article 5 — EXaCT-2 WES Platform (PMID 42014463)
🟢 Near-term implementable
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 7 | Unified WES + targeted depth + SCNA + fusions + oncogenic virus + BCR clonotypes in one assay is a meaningful technical advance; addresses known WES limitations in cancer gene coverage |
| Clinical Relevance | 6 | Reduces need for multiple sequential assays; clinically useful for tumor boards and precision oncology programs, but primarily a platform paper |
| Population Reach | 7 | Applicable to all solid tumor oncology patients requiring genomic profiling; large addressable population |
| Implementation Speed | 5 | Requires institutional adoption, bioinformatics infrastructure, and regulatory/lab accreditation; Weill Cornell positioning accelerates but does not ensure broad uptake |
| Evidence Strength | 6 | 244 matched tumor/normal pairs; benchmarking study design; Agilent COI on author list is a notable caveat; abstract-only |
Key quantitative result: ~400× depth for 1,400+ cancer genes; ~100× whole exome; improved sub-clonal mutation detection vs. standard WES (specific sensitivity values not in abstract).
External validation: Internal benchmarking only.
Main limitation: Single-institution validation; commercial COI (Agilent employees as authors); requires independent multi-center replication.
Equity implications: WES platforms are resource-intensive; primarily benefits patients at well-funded academic centers; global access concerns remain.
Evidence Maturity: Validated ✓ (within single-institution benchmarking context)
Article 6 — MCI and AD ML Diagnostics (PMID 42014714)
⚪ Promising but preliminary
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 6 | Identifying MCI heterogeneity (specifically prodromal AD subgroup) as the primary confounder in AD diagnostic models is a conceptually important finding for the field |
| Clinical Relevance | 5 | Clarifies why routine blood-test-based AD models underperform; doesn't yet provide a better model — diagnostic improvement is deferred |
| Population Reach | 8 | AD affects ~55 million people globally; a primary-care CBC-based screen would be transformative if achievable |
| Implementation Speed | 3 | Framework paper; next steps require better MCI subtyping tools before clinical translation |
| Evidence Strength | 5 | ADNI cohort (well-characterized); CatBoost ML; retrospective; sample size unspecified in abstract; medium confidence |
Key quantitative result: MCI subgroup degrades model performance (quantitative performance metrics not specified in abstract).
External validation: ADNI is a widely used benchmark cohort, providing indirect validation.
Main limitation: Sample size not reported; abstract-only; finding is primarily negative/clarifying rather than prescriptive.
Equity implications: ADNI cohort is predominantly white/North American — findings may not generalize to diverse populations; AD burden is rising fastest in LMICs.
Evidence Maturity: Exploratory ✓ (confirmed)
Article 7 — Sysmex XR-9000 Validation (PMID 42013012)
🟢 Near-term implementable
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 3 | Instrument validation study; incremental advance over existing analyzer; not scientifically novel |
| Clinical Relevance | 5 | Relevant to lab medicine practice; ensures XR-9000 meets clinical standards; minor MCHC/basophil discrepancies are practically manageable |
| Population Reach | 6 | CBC is the world's most common lab test; analyzer quality affects billions of tests annually |
| Implementation Speed | 8 | Standard lab procurement decision; no regulatory barriers beyond existing clearance |
| Evidence Strength | 6 | CLSI/ICSH guideline-compliant methodology; sample size not reported; abstract-only |
Key quantitative result: r²>0.99 linearity across key CBC parameters; minor MCHC imprecision above EFLM criteria at low concentrations only.
External validation: Compared to established XN-9100 as gold standard.
Main limitation: Sample size unreported; single-center; minor discrepancies at low concentrations require clinical interpretation.
Equity implications: Broad global impact — laboratory instrument quality directly affects diagnostic accuracy in all settings, including low-resource environments where CBC remains a primary diagnostic tool.
Evidence Maturity: Validated ✓ (confirmed, within scope of instrument validation)
Article 8 — Secondary Malignancies in DLBCL/FL (PMID 42014937)
⬜ Standard
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 5 | Subtype-specific SPSM data in FL vs. DLBCL adds granularity; thyroid cancer predominance is a novel sub-finding; nomogram is new but unvalidated externally |
| Clinical Relevance | 5 | Relevant for long-term survivorship planning; thyroid surveillance implication for FL patients is actionable |
| Population Reach | 5 | DLBCL and FL are among the most common lymphomas; SPSMs affect ~4–6% — moderate clinical impact |
| Implementation Speed | 4 | Nomogram requires external validation before clinical adoption |
| Evidence Strength | 4 | Single-center Chinese cohort; small SPSM subgroup (n=81); limited generalizability |
Key quantitative result: SPSM rate: FL 6.34% vs. DLBCL 3.63%; nomogram AUC 0.761.
External validation: Internal validation only.
Main limitation: Single-center, single-ethnicity, small SPSM subgroup; Chinese population may not generalize.
Equity implications: Chinese cohort data; generalizability to other ethnic groups uncertain.
Evidence Maturity: Exploratory ✓ (confirmed)
Article 9 — Chidamide + Cisplatin/Etoposide in DLBCL (PMID 42014876)
⚪ Promising but preliminary
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 7 | Pyroptosis via caspase-3/GSDME as mechanism for HDAC inhibitor combination is mechanistically novel and well-defined; immunogenic cell death reframing of an existing drug combination |
| Clinical Relevance | 3 | Preclinical only; capped per non-human study rule; chidamide is approved in China but not globally |
| Population Reach | 5 | DLBCL is the most common aggressive lymphoma; relapsed/refractory DLBCL has high unmet need |
| Implementation Speed | 2 | Preclinical stage; significant clinical trial development required |
| Evidence Strength | 4 | Cell lines + syngeneic mouse model; standard preclinical design; no human data |
Key quantitative result: CD8+ T cell depletion abolishes therapeutic benefit (confirming immune-mediated mechanism); quantitative tumor burden reduction not specified in abstract.
External validation: None.
Main limitation: Preclinical only; mouse syngeneic models do not fully recapitulate human DLBCL tumor microenvironment.
Equity implications: If translated, chidamide's China-approved status may create early-access disparities.
Evidence Maturity: Exploratory ✓ (confirmed)
Article 10 — HDAC8i + Venetoclax in KMT2A-r AML (PMID 42014858)
⚪ Promising but preliminary
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 8 | HDAC8-specific mechanism (STAT3 acetylation/degradation → MYC suppression) independent of TP53 is genuinely novel and addresses a critical clinical challenge |
| Clinical Relevance | 4 | Preclinical; capped per non-human study rule; TP53-independence is a particularly valuable translational feature for KMT2A-r AML |
| Population Reach | 5 | KMT2A-r AML is |
| Implementation Speed | 2 | Preclinical; HDAC8 inhibitors are not yet approved; trial development required |
| Evidence Strength | 5 | Mouse model + PDX + primary patient cells is a strong preclinical package; KMT2A::MLLT3 model is clinically relevant |
Key quantitative result: HDAC8i + Venetoclax synergistically reduces leukemia burden and prolongs survival in KMT2A-r models regardless of TP53 status (quantitative survival data not in abstract).
External validation: PDX from primary patient cells provides translational validation step.
Main limitation: No human trial data; HDAC8 selective inhibitors are not clinically advanced.
Equity implications: KMT2A-r AML disproportionately affects infants and young adults; TP53-independent mechanism addresses a known treatment failure mode.
Evidence Maturity: Exploratory ✓ (confirmed)
Article 11 — ctHPV-DNA in OPSCC Surveillance (Review) (PMID 42012400)
⬜ Standard
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 4 | Narrative synthesis of established findings; surveillance framework is useful but not new discovery |
| Clinical Relevance | 6 | Two-consecutive-positive-test trigger for imaging is clinically actionable; fills a guideline gap |
| Population Reach | 5 | HPV+ OPSCC is rising (HPV-related OPSCC now the most common HPV-associated cancer in the US); important but specialist audience |
| Implementation Speed | 5 | Framework is ready but assay standardization remains a barrier; not yet guideline-endorsed |
| Evidence Strength | 4 | Narrative review; no new primary data; synthesis quality depends on underlying studies |
Key quantitative result: ctHPV-DNA detects recurrence months before radiologic confirmation (specific lead times not in abstract).
External validation: Based on synthesis of existing studies.
Main limitation: Narrative (not systematic) review; assay standardization gap limits immediate implementation.
Equity implications: HPV-related OPSCC disproportionately affects middle-aged white men in high-income countries; HPV vaccination programs may shift demographics over time.
Evidence Maturity: Validated (with caveats — review-level synthesis)
Article 12 — Exosomal miRNA for Rectal CRT Response (PMID 42011875)
⚪ Promising but preliminary
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 6 | 5-miRNA exosomal panel + CEA for pCR prediction is novel in combination; exosomal miRNA panels for CRT response are an emerging but not novel concept |
| Clinical Relevance | 7 | pCR prediction pre-operatively could support organ preservation strategies (watch-and-wait); direct surgical decision impact |
| Population Reach | 6 | Locally advanced rectal cancer affects ~25,000 US cases/year; organ preservation has major quality-of-life implications |
| Implementation Speed | 4 | Exosome isolation and miRNA profiling not yet routine clinical lab practice; needs larger validation |
| Evidence Strength | 5 | Retrospective multicenter (2 centers), n=81; independent validation cohort AUC 0.87 is respectable; small N limits power |
Key quantitative result: AUC 0.90 (sens 0.82, spec 0.90) training; AUC 0.87 independent validation.
External validation: Independent multicenter validation cohort — a meaningful strength given small total N.
Main limitation: Small retrospective cohort; exosome methodology not standardized; miRNA panel requires prospective validation before clinical integration.
Equity implications: Organ preservation approach is particularly valuable in settings where surgical morbidity is higher; access to exosomal miRNA testing will be initially limited to specialized centers.
Evidence Maturity: Validated (within small-N multicenter retrospective context) → retain
Article 13 — PlasDroplex EV Detection (PMID 42011810)
⚪ Promising but preliminary
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 8 | Wash-free plasmonic droplet microfluidics for digital EV detection is a genuinely novel engineering platform; sub-zeptomolar LOD in 10 µL plasma is technically impressive |
| Clinical Relevance | 3 | Early-stage technology; AUC values are impressive but n=63 is insufficient for clinical validation; no head-to-head vs. current standard |
| Population Reach | 7 | If validated, applicable to prostate + lung cancer screening — two of the highest-burden cancers globally |
| Implementation Speed | 2 | Technology development stage; specialized microfluidic fabrication required; 5–10+ year translation timeline |
| Evidence Strength | 4 | Small clinical sample (n=63); single-center validation; medium classification confidence; abstract-only |
Key quantitative result: AUC 0.926/0.932 (PSA+/PSMA+ EV prostate cancer); AUC 0.998 (PD-L1 EV lung cancer); LOD 2,500–6,700 EVs/mL.
External validation: None.
Main limitation: Very small clinical N; technology readiness level is low; AUC 0.998 for lung cancer is likely overfitted at n=63.
Equity implications: If simplified into a point-of-care format, potential for broad access; but current microfluidic platform is far from deployable in LMICs.
Evidence Maturity: Exploratory ✓ (confirmed)
Article 14 — ddPCR BRAF ctDNA in Melanoma (PMID 42011804)
⬜ Standard
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 4 | Correlative ctDNA/PET-CT data is confirmatory rather than novel; LDH and lesion count as ctDNA predictors are well-established |
| Clinical Relevance | 5 | Supports targeted use of ddPCR ctDNA in high-burden melanoma; correlation with PET-CT MTV aids clinical framing |
| Population Reach | 5 | BRAF V600 melanoma is ~40–50% of melanoma cases; ~100,000 US melanoma diagnoses/year |
| Implementation Speed | 6 | ddPCR is available in specialized labs; findings support clinical guidance for existing assay use |
| Evidence Strength | 5 | Retrospective Mayo Clinic cohort, n=71; single-center; abstract-only; limited by design |
Key quantitative result: ctDNA positivity: LDH elevation OR 9.9, >10 lesions OR 11.3, younger age OR 11.8; PET-CT MTV correlation Pearson r=0.49.
External validation: None.
Main limitation: Small retrospective cohort; correlative study; does not establish clinical utility over standard biomarkers.
Evidence Maturity: Validated ✓ (within scope of correlative study)
Article 15 — Microbial Metabolome in Hematologic Malignancies (Review) (PMID 42014413)
⚪ Promising but preliminary
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 5 | Microbiome-oncology interface is established; metabolome focus adds specificity; review synthesizes rather than generates knowledge |
| Clinical Relevance | 4 | No actionable clinical guidance yet; framework for future trials |
| Population Reach | 6 | Hematologic malignancy patients broadly; transplant patients in particular |
| Implementation Speed | 2 | No validated clinical application exists yet |
| Evidence Strength | 3 | Review only; no primary data |
Evidence Maturity: Exploratory ✓
Article 16 — Genomic Medicine Is Failing Most of Humanity (PMID 42014456)
🟡 Underserved/high-risk populations
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 5 | The equity gap in genomics is well-documented; this commentary articulates the problem in a high-profile venue |
| Clinical Relevance | 5 | Influences research prioritization and policy; no direct patient care intervention |
| Population Reach | 10 | Concerns the majority of the global population (~85% non-European) |
| Implementation Speed | 3 | Systemic change; depends on research funding and policy reform |
| Evidence Strength | 3 | Commentary/opinion; no new primary data |
Evidence Maturity: Exploratory ✓
Article 17 — Gut-Brain Signalling in Obesity (Review) (PMID 42014861)
⚪ Promising but preliminary
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 6 | Identifying vagal remodeling and GLP-1 RA limitations as mechanistic insight is a useful synthesis; vagus nerve as underexplored target is modestly novel framing |
| Clinical Relevance | 5 | GLP-1 RA mechanism review informs prescriber understanding but doesn't change current prescribing; vagal targeting is far from clinical |
| Population Reach | 9 | Obesity affects ~1 billion adults globally; one of the highest-burden non-communicable diseases |
| Implementation Speed | 2 | Vagal neuromodulation as a new obesity therapy requires extensive development |
| Evidence Strength | 4 | Review; mixed human/animal evidence synthesis |
Evidence Maturity: Exploratory ✓
Article 18 — Exhaled VOC Diagnostics for AD (PMID 42014693)
⚪ Promising but preliminary
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 7 | Exhaled breath VOC profiling for AD diagnosis is a genuinely novel non-invasive approach; metabolic pathway identification (butyrate, pyruvate) adds biological depth |
| Clinical Relevance | 5 | 75% external validation accuracy is modest; distinguishing AD from non-AD dementia (90%) has meaningful clinical value if robustly validated |
| Population Reach | 8 | AD affects ~55 million people globally; a breath test would be transformative for primary care screening |
| Implementation Speed | 4 | VOC profiling requires specialized equipment; external validation drop from 93% to 75% is a caution flag |
| Evidence Strength | 5 | n=285, internal + external validation; high confidence; but 75% external accuracy and abstract-only limit strength |
Key quantitative result: Internal accuracy 0.93; external 0.75; AD vs. non-AD dementia accuracy 0.90.
Evidence Maturity: Exploratory ✓
Article 19 — CRP/Albumin Ratio in CCS/CTO (PMID 42012088)
🟢 Near-term implementable
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 4 | CAR as a composite biomarker is not new; application to coronary collateral circulation in CTO is a specific niche contribution |
| Clinical Relevance | 5 | CTO is a challenging management area; a routine biomarker for collateral prediction has practical utility |
| Population Reach | 5 | CCS/CTO is a defined cardiology subpopulation; not mass-population reach |
| Implementation Speed | 7 | CRP and albumin are universally available routine tests; low barrier to adoption |
| Evidence Strength | 4 | n=123, single-center, prospective but small; abstract-only |
Evidence Maturity: Exploratory ✓
Article 20 — Transcranial Vibrotactile Stimulation in Mice (PMID 42014786)
⚪ Promising but preliminary
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 5 | 40 Hz stimulation for AD is an active field; specific vibrotactile modality is a novel delivery mechanism |
| Clinical Relevance | 2 | Animal study only; capped per non-human study rule |
| Population Reach | 8 | AD/cognitive decline affects tens of millions; non-pharmacological interventions would have wide appeal |
| Implementation Speed | 2 | Preclinical; requires human validation and device development |
| Evidence Strength | 3 | Mouse model, scopolamine-induced impairment is a limited AD proxy; animal-only |
Evidence Maturity: Exploratory ✓
Article 21 — Single-Molecule Sensor Deep Learning (PMID 42014711)
⚪ Promising but preliminary
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 8 | Sub-attomolar detection via time-frequency DL decoding of tunneling signals is a physics/engineering advance of genuine novelty |
| Clinical Relevance | 2 | In vitro engineering study; no clinical application demonstrated; low classification confidence |
| Population Reach | 5 | Potentially broad if translated to diagnostics; currently speculative |
| Implementation Speed | 1 | Lab-stage technology; 10+ year translation timeline |
| Evidence Strength | 3 | In vitro validation; low confidence classification; abstract-only |
Evidence Maturity: Exploratory ✓
Article 22 — PMID 42014847 — Unreviewed High-Signal Article
⬜ Deferred
Abstract parse failed. Scored as placeholder only.
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | N/A | Cannot assess |
| Clinical Relevance | N/A | Cannot assess |
| Population Reach | N/A | Cannot assess |
| Implementation Speed | N/A | Cannot assess |
| Evidence Strength | N/A | Cannot assess |
Note: Top result in three simultaneous watchlist searches (CBC/ML, ctDNA, aging). Flagged for priority review in next run. Treat as potentially high-value deferred record.